These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33031539)

  • 21. Response to Letter to Editor Regarding "Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma".
    Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):e335-e336. PubMed ID: 32950694
    [No Abstract]   [Full Text] [Related]  

  • 22. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
    Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
    Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy.
    Spiegel JY; Dahiya S; Jain MD; Tamaresis J; Nastoupil LJ; Jacobs MT; Ghobadi A; Lin Y; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Goy A; Vu K; Andreadis C; Munoz J; Bennani NN; Vose JM; Dorritie KA; Neelapu SS; Locke FL; Rapoport AP; Hill BT; Miklos DB
    Blood; 2021 Apr; 137(13):1832-1835. PubMed ID: 33156925
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.
    Bouchkouj N; Zimmerman M; Kasamon YL; Wang C; Dai T; Xu Z; Wang X; Theoret M; Purohit-Sheth T; George B
    Oncologist; 2022 Jul; 27(7):587-594. PubMed ID: 35403693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
    Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
    Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response.
    Jallouk AP; Gouni S; Westin J; Feng L; Mistry H; Steiner RE; James J; Noorani M; Horowitz S; Puebla-Osorio N; Fayad LE; Iyer SP; Hawkins M; Flowers CR; Ahmed S; Nastoupil LJ; Kebriaei P; Shpall EJ; Neelapu SS; Nieto Y; Strati P
    Haematologica; 2023 Apr; 108(4):1163-1167. PubMed ID: 36384251
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome.
    Kittai AS; Bond DA; William B; Saad A; Penza S; Efebera Y; Larkin K; Wall SA; Choe HK; Bhatnagar B; Vasu S; Brammer J; Shindiapina P; Long M; Mims A; O'Donnell L; Bhat SA; Rogers KA; Woyach JA; Byrd JC; Jaglowski SM
    Blood Adv; 2020 Oct; 4(19):4648-4652. PubMed ID: 33002129
    [No Abstract]   [Full Text] [Related]  

  • 30. CD19-directed CAR T-cell therapy in B-cell NHL.
    Kersten MJ; Spanjaart AM; Thieblemont C
    Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.
    Rejeski K; Kunz WG; Rudelius M; Bücklein V; Blumenberg V; Schmidt C; Karschnia P; Schöberl F; Dimitriadis K; von Baumgarten L; Stemmler J; Weigert O; Dreyling M; von Bergwelt-Baildon M; Subklewe M
    BMC Infect Dis; 2021 Jan; 21(1):121. PubMed ID: 33509115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
    Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
    J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.
    Neelapu SS; Jacobson CA; Oluwole OO; Munoz J; Deol A; Miklos DB; Bartlett NL; Braunschweig I; Jiang Y; Kim JJ; Zheng L; Rossi JM; Locke FL
    Blood; 2020 Jun; 135(23):2106-2109. PubMed ID: 32181801
    [No Abstract]   [Full Text] [Related]  

  • 34. Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy.
    Byrne M; Oluwole OO; Savani B; Majhail NS; Hill BT; Locke FL
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):e344-e351. PubMed ID: 31279751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
    Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
    J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
    Pinnix CC; Gunther JR; Dabaja BS; Strati P; Fang P; Hawkins MC; Adkins S; Westin J; Ahmed S; Fayad L; Lee HJ; Nair R; Steiner RE; Iyer SP; Rodriguez MA; Wang M; Flowers C; Neelapu SS; Nastoupil LJ
    Blood Adv; 2020 Jul; 4(13):2871-2883. PubMed ID: 32589728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
    Baird JH; Epstein DJ; Tamaresis JS; Ehlinger Z; Spiegel JY; Craig J; Claire GK; Frank MJ; Muffly L; Shiraz P; Meyer E; Arai S; Brown JW; Johnston L; Lowsky R; Negrin RS; Rezvani AR; Weng WK; Latchford T; Sahaf B; Mackall CL; Miklos DB; Sidana S
    Blood Adv; 2021 Jan; 5(1):143-155. PubMed ID: 33570626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma.
    Raychaudhuri R; Qualtieri J; Garfall AL
    Am J Hematol; 2020 Jan; 95(1):E28-E30. PubMed ID: 31725923
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.